Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction.

For over a century, there has been intense debate as to the reason why some cardiac stresses are pathological and others are physiological. One long-standing theory is that physiological overloads such as exercise are intermittent, while pathological overloads such as hypertension are chronic. In this study, we hypothesized that the nature of the stress on the heart, rather than its duration, is the key determinant of the maladaptive phenotype. To test this, we applied intermittent pressure overload on the hearts of mice and tested the roles of duration and nature of the stress on the development of cardiac failure. Despite a mild hypertrophic response, preserved systolic function, and a favorable fetal gene expression profile, hearts exposed to intermittent pressure overload displayed pathological features. Importantly, intermittent pressure overload caused diastolic dysfunction, altered beta-adrenergic receptor (betaAR) function, and vascular rarefaction before the development of cardiac hypertrophy, which were largely normalized by preventing the recruitment of PI3K by betaAR kinase 1 to ligand-activated receptors. Thus stress-induced activation of pathogenic signaling pathways, not the duration of stress or the hypertrophic growth per se, is the molecular trigger of cardiac dysfunction.

[1]  W. Koch,et al.  Genetic Alterations That Inhibit In Vivo Pressure-Overload Hypertrophy Prevent Cardiac Dysfunction Despite Increased Wall Stress , 2002, Circulation.

[2]  R. S. Williams,et al.  Skeletal muscle adaptation in response to voluntary running in Ca2+/calmodulin-dependent protein kinase IV-deficient mice. , 2004, American journal of physiology. Cell physiology.

[3]  C. Parent Faculty Opinions recommendation of PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. , 2004 .

[4]  S. Yusuf,et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. , 2000 .

[5]  R. Lefkowitz,et al.  When 7 transmembrane receptors are not G protein-coupled receptors. , 2005, The Journal of clinical investigation.

[6]  J. Knowles,et al.  Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. , 2001, The Journal of clinical investigation.

[7]  R. Kitsis,et al.  The MEK1–ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice , 2000, The EMBO journal.

[8]  A. Zeiher,et al.  Fas receptor signaling inhibits glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload. , 2002, The Journal of clinical investigation.

[9]  S. Houser,et al.  Myocyte recovery after mechanical circulatory support in humans with end-stage heart failure. , 1998, Circulation.

[10]  Lan Mao,et al.  Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy. , 2001, Journal of the American College of Cardiology.

[11]  M. Caron,et al.  Agonist-dependent Recruitment of Phosphoinositide 3-Kinase to the Membrane by b-Adrenergic Receptor Kinase 1 A ROLE IN RECEPTOR SEQUESTRATION* , 2001 .

[12]  M. Caron,et al.  Agonist-dependent Recruitment of Phosphoinositide 3-Kinase to the Membrane by β-Adrenergic Receptor Kinase 1 , 2001, The Journal of Biological Chemistry.

[13]  W. Koch,et al.  Vascular rarefaction in peripheral skeletal muscle after experimental heart failure. , 2003, American journal of physiology. Heart and circulatory physiology.

[14]  P. Kang,et al.  Phosphoinositide 3-kinase(p110α) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[15]  R. Lefkowitz,et al.  Cardiac beta ARK1 inhibition prolongs survival and augments beta blocker therapy in a mouse model of severe heart failure. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Anthony J. Muslin,et al.  RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload. , 1999, The Journal of clinical investigation.

[17]  J. Knowles,et al.  Ventricular expression of natriuretic peptides in Npr1(-/-) mice with cardiac hypertrophy and fibrosis. , 2002, American journal of physiology. Heart and circulatory physiology.

[18]  M. Cho,et al.  Defective β-Adrenergic Receptor Signaling Precedes the Development of Dilated Cardiomyopathy in Transgenic Mice with Calsequestrin Overexpression* , 1999, The Journal of Biological Chemistry.

[19]  J. Hedner,et al.  Impairment of vascular endothelial function and left ventricular filling : association with the severity of apnea-induced hypoxemia during sleep. , 2001, Chest.

[20]  S. Vatner,et al.  The MEKK1-JNK pathway plays a protective role in pressure overload but does not mediate cardiac hypertrophy. , 2002, The Journal of clinical investigation.

[21]  F. Meerson Compensatory Hyperfunction of the Heart and Cardiac Insufficiency , 1962, Circulation research.

[22]  C W Whitney,et al.  Sleep-disordered breathing and cardiovascular disease: cross-sectional results of the Sleep Heart Health Study. , 2001, American journal of respiratory and critical care medicine.

[23]  F. Abboud,et al.  Sympathetic neural mechanisms in obstructive sleep apnea. , 1995, The Journal of clinical investigation.

[24]  Dianqing Wu,et al.  Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure. , 2003, The Journal of clinical investigation.

[25]  J. Ross,et al.  Loss of a gp130 Cardiac Muscle Cell Survival Pathway Is a Critical Event in the Onset of Heart Failure during Biomechanical Stress , 1999, Cell.

[26]  E. Olson,et al.  Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. , 1999, Circulation research.

[27]  R. Quaife,et al.  Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. , 2002, The New England journal of medicine.

[28]  R. Lefkowitz,et al.  Cardiac βARK1 inhibition prolongs survival and augments β blocker therapy in a mouse model of severe heart failure , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  G. Dorn,et al.  Protein kinase cascades in the regulation of cardiac hypertrophy. , 2005, The Journal of clinical investigation.

[30]  N. Christensen,et al.  Sympathetic nervous activity during exercise. , 1983, Annual review of physiology.

[31]  S. Gordon Faculty Opinions recommendation of Protein kinase activity of phosphoinositide 3-kinase regulates beta-adrenergic receptor endocytosis. , 2005 .

[32]  C. Kahn,et al.  Regulation of Myocardial Contractility and Cell Size by Distinct PI3K-PTEN Signaling Pathways , 2002, Cell.

[33]  Paul A. Overbeek,et al.  TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice , 2000, Nature Medicine.

[34]  M. Nieminen,et al.  Prognostic significance of left ventricular mass change during treatment of hypertension. , 2004, JAMA.

[35]  B. Groves,et al.  Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. , 1997, The Journal of clinical investigation.

[36]  M. Caron,et al.  Phosphoinositide 3-kinase regulates β2-adrenergic receptor endocytosis by AP-2 recruitment to the receptor/β-arrestin complex , 2002, The Journal of cell biology.

[37]  L. Silengo,et al.  PI3Kγ Modulates the Cardiac Response to Chronic Pressure Overload by Distinct Kinase-Dependent and -Independent Effects , 2004, Cell.

[38]  Robert J. Lefkowitz,et al.  Seven-transmembrane-spanning receptors and heart function , 2002, Nature.

[39]  I. Shiojima,et al.  Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. , 2005, The Journal of clinical investigation.

[40]  J. Ross,et al.  Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[41]  D. Levy,et al.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.

[42]  J. Weiss,et al.  Time constant of isovolumic pressure fall: determinants in the working left ventricle. , 1978, The American journal of physiology.

[43]  L. Leinwand,et al.  Myosin heavy chain gene expression in human heart failure. , 1997, The Journal of clinical investigation.

[44]  H. Gavras,et al.  Conditioning effects of chronic infusions of dobutamine. Comparison with exercise training. , 1979, The Journal of clinical investigation.

[45]  R. Lefkowitz,et al.  Level of &bgr;-Adrenergic Receptor Kinase 1 Inhibition Determines Degree of Cardiac Dysfunction After Chronic Pressure Overload–Induced Heart Failure , 2005 .

[46]  Luigi Fratta,et al.  Melusin, a muscle-specific integrin β1–interacting protein, is required to prevent cardiac failure in response to chronic pressure overload , 2003, Nature Medicine.

[47]  J. Ross,et al.  Hyperfunction with normal inotropic state of the hypertrophied left ventricle. , 1977, The American journal of physiology.

[48]  Michael S Lauer,et al.  Left ventricular hypertrophy: the next treatable, silent killer? , 2004, JAMA.

[49]  W. Koch,et al.  Mechanism of β-Adrenergic Receptor Desensitization in Cardiac Hypertrophy Is Increased β-Adrenergic Receptor Kinase* , 1997, The Journal of Biological Chemistry.

[50]  H. Suga,et al.  Heart size-independent analysis of myocardial function in murine pressure overload hypertrophy. , 2002, American journal of physiology. Heart and circulatory physiology.

[51]  H. Rockman,et al.  Restoration of &bgr;-Adrenergic Receptor Signaling and Contractile Function in Heart Failure by Disruption of the &bgr;ARK1/Phosphoinositide 3-Kinase Complex , 2005, Circulation.

[52]  S. V. Prasad,et al.  Protein kinase activity of phosphoinositide 3-kinase regulates β-adrenergic receptor endocytosis , 2005, Nature Cell Biology.

[53]  L. Leinwand,et al.  Myosin heavy chain isoform expression in the failing and nonfailing human heart. , 2000, Circulation research.

[54]  K. Chien,et al.  Erratum: Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy (Proc. Natl. Acad. Sci. USA (September 1991) 88 (8277-8281)) , 1991 .

[55]  E. Olson,et al.  Hypertrophy of the heart: a new therapeutic target? , 2004, Circulation.

[56]  Robert J. Lefkowitz,et al.  Transduction of Receptor Signals by ß-Arrestins , 2005, Science.

[57]  W. Gaasch,et al.  Myocardial relaxation. II. Hemodynamic determinants of rate of left ventricular isovolumic pressure decline. , 1980, The American journal of physiology.

[58]  H. Rockman,et al.  Targeted inhibition of beta-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves beta-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression. , 2005, Journal of the American College of Cardiology.

[59]  S. Kudoh,et al.  Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II , 2004, Nature Cell Biology.